T&R Biofab announced on the 2nd that it has obtained product approval from the Ministry of Food and Drug Safety (MFDS) for Reprofoam and Bonofoam, a product line of polyurethane (PU) foam wound dressings (foam bandages) developed by the company.
This approval marks the expansion of T&R Biofab's lineup of commercialized wound dressing products, with the addition of a polyurethane foam bandage, following the recent functional foam bandage and drug-containing foam bandage products. The new foam bandage maximizes the properties of polyurethane, including ▲maintaining a moist environment ▲absorbing exudates ▲preventing wound contamination, and features faster wound healing than existing gauze-type dressings. Furthermore, the foam bandage is designed to be conveniently applied to wounds that can easily occur in everyday life, such as on the fingers, by implementing the existing dressing type product into a bandage type.
This product uses silicone adhesive, making it suitable for the sensitive skin of children and the elderly. It is very thin at 0.5mm, so it has excellent skin adhesion and has the advantage of being easy to apply to curved areas due to its high elasticity.
T&R Biofab also anticipates receiving regulatory approval for a hemostatic product containing VdECM (vascular-derived extracellular matrix) within the first quarter of this year. This product is an absorbable, complex hemostatic agent used to control bleeding in blood vessels and other body tissues during surgical procedures. In addition to its hemostatic and adhesion-preventing properties, the VdECM component promotes regeneration and healing of damaged tissue.
“Sales of medical products specialized in regenerative medicine, such as foam-type wound dressings, ointment-type wound dressings, and hemostatic agents, are expected to increase significantly,” said Seung-kyo Jeong, Executive Director of the Strategic Planning Division at T&R Biofab. “Sales from this segment are expected to account for more than 30% of the company’s total projected sales of 30 billion won this year.” He also emphasized, “Growth in the medical sector will accelerate further with the full-scale entry of ointment-type wound dressings into the Chinese market and the expected US FDA approval of CFI, a neurosurgical product.”
- See more related articles
You must be logged in to post a comment.